Physician profile
Carlos E Jimenez
NPI 1689636987
$4,584.52
in general payments reported to CMS, 2019-2025
20 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $1,458 · 2023: $877 · 2024: $761 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.16 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,013.42 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $796.51 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $600.96 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $404.90 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.22 | 2022-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $325.43 | 2021-2023 | Korlym |
| Abbvie INC. | $312.66 | 2021-2024 | |
| Astellas Pharma US INC | $210.65 | 2023-2025 | Veozah |
| Amgen INC. | $197.56 | 2024-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $72.31 | 2021-2022 | |
| Abbott Laboratories | $59.70 | 2021-2022 | |
| Exact Sciences Corporation | $50.81 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $36.89 | 2021 | |
| Glaxosmithkline, LLC. | $34.76 | 2022-2023 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $32.12 | 2022-2024 | Zoryve |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.75 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $27.73 | 2025 | Symbravo |
| Lifescan, INC. | $23.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.